Retogatein delays Type 1 Diabetes onset by over five years
Diamyd Medical's drug candidate retogatein has significantly delayed the onset of Stage 3 Type 1 Diabetes by over five years in a genetically defined subgroup of children. This is according to long-term follow-up data from the DiAPREV-IT study.
Diamyd Medical's drug candidate retogatein has demonstrated a significant ability to delay the onset of Type 1 Diabetes. Two subcutaneous injections of retogatein delayed the onset of Stage 3 Type 1 Diabetes by over five years in a genetically defined subgroup of children, according to long-term follow-up data from the randomized, placebo-controlled DiAPREV-IT study. The results are currently in press for publication in the journal Diabetologia.
Professor Helena Elding Larsson at Lund University stated that the results support retogatein as a potential disease-modifying therapy for children with GAD antibodies and at least one other islet autoantibody, belonging to a genetically defined responder group. The study was led by Professor Helena Elding Larsson.
This delay in diabetes onset could provide patients and healthcare systems with crucial time to prepare for disease management and potentially mitigate long-term complications. Type 1 Diabetes is an autoimmune condition where the body's immune system attacks and destroys insulin-producing beta cells in the pancreas.
The study's findings are expected to pave the way for new therapeutic strategies in the prevention and treatment of Type 1 Diabetes.